Cytochrome P450 3A gene variation, steroid hormone serum levels and prostate cancer - The Rotterdam Study

Steroids

Volumn 75, Issue 12, 2010, Pages 1024-1032

  Siemes, Claire ^a   Visser, Loes E ^a   De Jong, Frank H ^a   Coebergh, Jan Willem W ^a   Uitterlinden, André G ^a   Hofman, Albert ^a   Stricker, Bruno H Ch ^a   Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cytochrome P450 3A; Polymorphism; Prostate cancer; Steroid hormone levels

Indexed keywords

ANDROSTENEDIONE; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; ESTRADIOL; ESTRONE; ESTRONE SULFATE; PRASTERONE SULFATE; STEROID HORMONE; TESTOSTERONE;

ADULT; AGED; ALLELE; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROTEIN EXPRESSION; WILD TYPE;

AGED; COHORT STUDIES; CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; STEROIDS;

EID: 77955924260     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2010.07.001     Document Type: Article

References (40)

1. A. Loukola, M. Chadha, S.G. Penn, D. Rank, D.V. Conti, and D. Thompson Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2 Eur J Hum Genet 12 2004 321 332
2. C. Zeigler-Johnson, T. Friebel, A.H. Walker, Y. Wang, E. Spangler, and S. Panossian CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer Cancer Res 64 2004 8461 8467
3. A. Gsur, E. Feik, and S. Madersbacher Genetic polymorphisms and prostate cancer risk World J Urol 21 2004 414 423
4. OMIM 2006, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM.
5. C. Finta, and P.G. Zaphiropoulos Intergenic mRNA molecules resulting from trans-splicing J Biol Chem 277 2002 5882 5890
6. T.L. Domanski, C. Finta, J.R. Halpert, and P.G. Zaphiropoulos cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450 Mol Pharmacol 59 2001 386 392
7. D.J. Waxman, C. Attisano, F.P. Guengerich, and D.P. Lapenson Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme Arch Biochem Biophys 263 1988 424 436
8. D.J. Waxman, D.P. Lapenson, T. Aoyama, H.V. Gelboin, F.J. Gonzalez, and K. Korzekwa Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s Arch Biochem Biophys 290 1991 160 166
9. A.J. Lee, A.H. Conney, and B.T. Zhu Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol Cancer Res 63 2003 6532 6536
10. K.K. Miller, J. Cai, S.L. Ripp, W.M. Pierce Jr., T.H. Rushmore, and R.A. Prough Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450 Drug Metab Dispos 32 2004 305 313
11. T.R. Rebbeck, J.M. Jaffe, A.H. Walker, A.J. Wein, and S.B. Malkowicz Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 90 1998 1225 1229
12. P.L. Paris, P.A. Kupelian, J.M. Hall, T.L. Williams, H. Levin, and E.A. Klein Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients Cancer Epidemiol Biomarkers Prev 8 1999 901 905
13. M.T. Tayeb, C. Clark, L. Sharp, N.E. Haites, P.H. Rooney, and G.I. Murray CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia Oncol Rep 9 2002 653 655
14. R.A. Kittles, W. Chen, R.K. Panguluri, C. Ahaghotu, A. Jackson, and C.A. Adebamowo CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110 2002 553 560
15. S.J. Plummer, D.V. Conti, P.L. Paris, A.P. Curran, G. Casey, and J.S. Witte CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer Cancer Epidemiol Biomarkers Prev 12 2003 928 932
16. A. Westlind, L. Lofberg, N. Tindberg, T.B. Andersson, and M. Ingelman-Sundberg Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region Biochem Biophys Res Commun 259 1999 201 205
17. B. Amirimani, A.H. Walker, B.L. Weber, and T.R. Rebbeck Response: remodification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 91 1999 1588 1590
18. B. Amirimani, B. Ning, A.C. Deitz, B.L. Weber, F.F. Kadlubar, and T.R. Rebbeck Increased transcriptional activity of the CYP3A4*1B promoter variant Environ Mol Mutagen 42 2003 299 305
19. Y. Ando, T. Tateishi, Y. Sekido, T. Yamamoto, T. Satoh, and Y. Hasegawa Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 91 1999 1587 1590
20. A.B. Spurdle, B. Goodwin, E. Hodgson, J.L. Hopper, X. Chen, and D.M. Purdie The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer Pharmacogenetics 12 2002 355 366
21. H. Hamzeiy, V. Bombail, N. Plant, G. Gibson, and P. Goldfarb Transcriptional regulation of cytochrome P4503A4 gene expression: effects of inherited mutations in the 5′-flanking region Xenobiotica 33 2003 1085 1095
22. M.D. Floyd, G. Gervasini, A.L. Masica, G. Mayo, A.L. George Jr., and K. Bhat Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women Pharmacogenetics 13 2003 595 606
23. T.R. Rebbeck More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 J Natl Cancer Inst 92 2000 76
24. M. Schirmer, M.R. Toliat, M. Haberl, A. Suk, L.K. Kandem, and K. Klein Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations Pharmacogenet Genomics 16 2006 59 71
25. A. Stone, L.D. Ratnasinghe, G.L. Emerson, R. Modali, T. Lehman, and G. Runnels CYP3A43 Pro(340)Ala polymorphism and prostate cancer risk in African Americans and Caucasians Cancer Epidemiol Biomarkers Prev 14 2005 1257 1261
26. A. Hofman, M.M. Breteler, C.M. van Duijn, G.P. Krestin, H.A. Pols, and B.H. Stricker The Rotterdam Study: objectives and design update Eur J Epidemiol 22 2007 819 829
27. R. Sodergard, T. Backstrom, V. Shanbhag, and H. Carstensen Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature J Steroid Biochem 16 1982 801 810
28. A.W. van den Beld, F.H. de Jong, D.E. Grobbee, H.A. Pols, and S.W. Lamberts Measures of bioavailable serum testosterone and estradiol and their relationships with muscle strength, bone density, and body composition in elderly men J Clin Endocrinol Metab 85 2000 3276 3282
29. K.L. Blauer, M. Poth, W.M. Rogers, and E.W. Bernton Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation Endocrinology 129 1991 3174 3179
30. M. May, E. Holmes, W. Rogers, and M. Poth Protection from glucocorticoid induced thymic involution by dehydroepiandrosterone Life Sci 46 1990 1627 1631
31. Y. Shafagoj, J. Opoku, D. Qureshi, W. Regelson, and M. Kalimi Dehydroepiandrosterone prevents dexamethasone-induced hypertension in rats Am J Physiol 263 1992 E210 E213
32. N.J. Horton, and N.M. Laird Maximum likelihood analysis of generalized linear models with missing covariates Stat Methods Med Res 8 1999 37 50
33. P. Smit, R.H. van Schaik, M. van der Werf, A.W. van den Beld, J.W. Koper, and J. Lindemans A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels J Clin Endocrinol Metab 90 2005 5313 5316
34. S. Legrain, and L. Girard Pharmacology and therapeutic effects of dehydroepiandrosterone in older subjects Drugs Aging 20 2003 949 967
35. W. de Ronde, A. Hofman, H.A. Pols, and F.H. de Jong A direct approach to the estimation of the origin of oestrogens and androgens in elderly men by comparison with hormone levels in postmenopausal women Eur J Endocrinol 152 2005 261 268
36. L. Zhenhua, N. Tsuchiya, S. Narita, T. Inoue, Y. Horikawa, and Kakinuma CYP3A5 gene polymorphism and risk of prostate cancer in a Japanese population Cancer Lett 225 2005 237 243
37. D. Bangsi, J. Zhou, Y. Sun, N.P. Patel, L.L. Darga, and L.K. Heilbrun Impact of a genetic variant in CYP3A4 on risk and clinical presentation of prostate cancer among white and African-American men Urol Oncol 24 2006 21 27
38. M.T. Tayeb, C. Clark, N.E. Haites, L. Sharp, G.I. Murray, and H.L. McLeod CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia Br J Cancer 88 2003 928 932
39. HapMap Project; 2006. Available at http://www.hapmap.org/.
40. S.W. Lamberts, A.W. van den Beld, and A.J. van der Lely The endocrinology of aging Science 278 2007 419 424